Whole Body PET-MRI in Paediatric and Adolescent Lymphoma

Lymphoma Clinical Trial

— PET/MRI  

Official title:

Feasibility of Using Whole Body PET-MRI to Stage and Restage Paediatric and Adolescent Hodgkin Lymphoma - a Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02935348
• Other study ID #: 13/0268
• Status: Recruiting
• Phase: N/A
• First received: December 3, 2015
• Last updated: October 13, 2016
• Start date: February 2014
• Est. completion date: May 2017

Study information

• Verified date: December 2015
• Source: University College, London
• Contact: Joey J Clemente
• Phone: 02034479094
• Email: joey.clemente[@]uclh.nhs.uk
• Is FDA regulated: No
• Health authority: United Kingdom: National Institute for Health ResearchUnited Kingdom: Research Ethics Committee
• Study type: Observational

Clinical Trial Summary

Children and adolescents with Hodgkin lymphoma currently undergo multiple investigations including a separate PET and MRI scans during their treatment.

Investigators want to investigate if a combined PET-MRI scan could give the same information.

Children who join our study will have an extra scan twice during their treatment

Description:

Children and adolescents with Hodgkin lymphoma currently undergo multiple investigations including a separate PET and MRI scans during their treatment.

Investigators want to investigate if a combined PET-MRI scan could give the same information.

Children who join our study will have an extra scan twice during their treatment

Routine whole body clinical MRI will be performed according to current clinical standard of care. Axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of T1 and T2 weighted sequences, with and without gadolinium administration.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: May 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 20 Years

Eligibility

Inclusion Criteria:

1. Suspected or histologically confirmed Hodgkin lymphoma

2. Male or female participants

3. Age 0-20 years inclusive

4. Entered into the EuroNet PHL-C1 trial, LP1 trial or successor Euronet trials, including Euronet PHL C2 due to open from 2013 onwards or planned to receive chemotherapy regimens of said trials without being formally entered into the trial.

5. Participant/Guardian/Parental written informed consent

Exclusion Criteria:

1. Participants with contraindications to MRI (including cardiac pacemakers or non-MRI compatible intracranial vascular clips)

2. Participants who are pregnant or nursing

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Lymphoma

Intervention

Radiation:
• Whole Body MRI
Routine whole body clinical MRI will be performed according to current clinical standard of care. Axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of T1 and T2 weighted sequences, with and without gadolinium administration.

Locations

Country	Name	City	State
United Kingdom	Centre for Medical Imaging	London

Sponsors (1)

Lead Sponsor	Collaborator
University College, London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The investigator will determine the technical feasibility of performing functional co-registered combined PET-MRI in this patient group using diffusion-weighted MR imaging.		3 years	No